Clinical trials: Dapagliflozin
Type 2 Diabetes
The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes
The study is a randomised double blind placebo control cross over trial with 4 weeks washout period. The expected duration of participant participation is 103 days.
- Trial name
- SINGLED (NCT04219124)
- Testing
- IMP oral tablet
- Where
- United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Healthy
Bioequivalence Study of Dapagliflozin 10 mg Film-coated Tablets
The study was an open-label, randomized, single-dose, two-period, two-sequence, two-day crossover study, conducted to find out whether the dapagliflozin 10 mg film-coated tablet produced by PT Dexa Medica (test drug) was…
- Trial name
- NCT06127212
- Testing
- Dapagliflozin 10 mg film-coated tablet, Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia
- Where
- Indonesia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Dexa Medica Group
T2DM (Type 2 Diabetes Mellitus)
The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2
To evaluate a pharmacokinetic drug interaction between AJU-A51R1 and AJU-A51R2 in healthy male volunteers.
- Trial name
- NCT04970940
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AJU Pharm Co., Ltd.
Diabetes Mellitus, Type 2
Pharmacokinetic Drug Interaction Study With Dapagliflozin and Glimepiride in Healthy Subjects
The purpose of the study is to determine the effect of glimepiride on dapagliflozin and the effect of dapagliflozin on glimepiride in healthy volunteers.
- Trial name
- NCT00562250
- Testing
- Dapagliflozin, Glimepiride, Dapagliflozin + Glimepiride
- Where
- Argentina
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)
It is anticipated that 7 days of oral administration of 10 mg dapagliflozin will reduce the renal glucose reabsorption similarly in healthy subjects and in subjects with T2DM.
- Trial name
- NCT01165268
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects
In this integrated, Phase I study, the safety, tolerability, food effect, and pharmacokinetic (PK) properties of Fixed-Dose Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR and Dapagliflozin / Metformin XR…
- Trial name
- NCT03138356
- Testing
- 2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet, 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet, 5 mg dapagliflozin / 850 mg metformin XR FDC
- Where
- United Kingdom
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Kidney Diseases
DYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve
This is a feasibility study to assess new, more practical ways of measuring renal reserve.
- Trial name
- DYNAMO (NCT06572215)
- Testing
- Dapagliflozin
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- King's College Hospital NHS Trust
Type 2 Diabetes Mellitus
To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately
This is an open-label, randomised study to compare the similarity of a combination Dapagliflozin/Metformin tablet with the two drugs administered separately under fasting and fed conditions in healthy volunteers.
- Trial name
- NCT01535677
- Testing
- Dapagliflozin + Glucophage tablet fasted, Dapagliflozin/metformin IR FDC tablet fasted, Dapagliflozin + Glucophage tablet fed
- Where
- United Kingdom
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Nephropathy, Hypoxia
Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes
Background: Inhibiting the sodium-glucose cotransporter-2 (SGLT2) has been observed to reduce risk of cardiovascular events and kidney failure in type 2 diabetes.
- Conditions
- Nephropathy, Hypoxia, Mitochondrial Alteration, Type 1 Diabetes
- Trial name
- Astronaut (NCT04193566)
- Testing
- Forxiga
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Steno Diabetes Center Copenhagen
Healthy
Study to Assess the Effect of Food on Combination Dapagliflozin/Metformin Tablet in Healthy Volunteers
The purpose of this study is to determine whether treatment with a fixed dose combination dapagliflozin/metformin tablet is affected by food.
- Trial name
- NCT01156246
- Testing
- Dapagliflozin/Metformin
- Where
- Sweden
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes, Metabolically Healthy Controls
Effects of SGLT-2 Inhibition on Hepatic Glucose and Energy Metabolism
Inhibition of SGLT2 by specific inhibitors has been shown to reduce the renal threshold for glucose excretion in patients with type 2 diabetes mellitus (T2DM) and control subjects leading to significant renal glucose loss even in…
- Trial name
- NCT02558270
- Testing
- Dapagliflozin
- Where
- Austria
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Aging
SGLT2 Inhibition in Older Obese Adults With Pre-diabetes
Inhibitors of the sodium-glucose co-transporter (SGLT2) are FDA-approved for the treatment of type 2 diabetes (T2DM). Their mechanism of action involves lowering of blood glucose concentration secondary to increased glucose…
- Trial name
- SGLT2i (NCT04401904)
- Testing
- Dapagliflozin 10 mg, Nutritional counseling
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)
Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
A Study to Assess the Bioequivalence of the fixed dose combination (FDC) of Dapagliflozin and Sitagliptin, and Dapagliflozin 10 mg and Sitagliptin 100 mg administered as individual tablets in Healthy Subject
- Trial name
- NCT05266404
- Testing
- Dapagliflozin/sitagliptin FDC, Sitagliptin, Dapagliflozin
- Where
- Germany
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus
Improving HbA1c Levels by Methylcobalamin Vitamin in Diabetic Volunteers
The current study was conducted to evaluate the prognostic implications of vitamin B12 admission on BMI and HbA1c levels in type 2 diabetic patients treated with Dapagliflozin as a routine medication.
- Trial name
- NCT06241638
- Testing
- Vitamin B12 0.5 MG/ACTUAT, Dapagliflozin 10mg Tab
- Where
- Jordan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Al-Balqa Applied University
Type 2 Diabetes Mellitus
Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects
The purpose of this study is determine that Dapagliflozin has no effect on the pharmacokinetics (PK) or pharmacodynamics (PD) of warfarin when dapagliflozin is coadministered with warfarin.
- Trial name
- NCT00904176
- Testing
- Dapagliflozin, Warfarin, Digoxin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Heart Failure
Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy Volunteers
The primary purpose of the study is to evaluate relative bioavailability of AZD9977 and dapagliflozin and compare the plasma concentration time profiles after dosing with different capsule formulations containing both AZD9977 and…
- Trial name
- NCT04798222
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)
The purpose of this study is to demonstrate the bioequivalence (BE) of Saxagliptin and Dapagliflozin from a 2.5-mg Saxagliptin/5-mg Dapagliflozin FDC tablet after oral administration relative to 2.5-mg Saxagliptin and 5-mg…
- Trial name
- NCT02060201
- Testing
- Saxagliptin, Dapagliflozin, Saxagliptin/Dapagliflozin FDC
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants
The purpose of this study is to evaluate whether the pharmacokinetics (body concentrations/metabolism of the drug) of Saxagliptin and Dapagliflozin are affected when they are administered together
- Trial name
- NCT01662999
- Testing
- Saxagliptin, Dapagliflozin
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Gemigliptin, Dapagliflozin, Empagliflozin DDI Study
gemigliptin,SGLT-2i DDI study
- Trial name
- NCT03565458
- Testing
- Gemigliptin, Dapagliflozin, Empagliflozin
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- LG Chem
Diabetes Mellitus, Type 2
A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.
To perform a comparative evaluation on the pharmacokinetics and the safety after administration of "BR3003" and co-administration of "BR3003B" and "BR3003C" in healthy adults.
- Trial name
- NCT05411965
- Testing
- BR3003(T), BR3003B(R1), BR3003C(R2)
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd